durvalumab (Imfinzi)

following a full submission assessed under the end of life medicine process:

durvalumab (Imfinzi®) is not recommended for use within NHSScotland.

Indication under review: In combination with tremelimumab for the first-line treatment of
adults with advanced or unresectable hepatocellular carcinoma (HCC).

In an open-label phase III study durvalumab in combination with tremelimumab was
associated with statistically significant improvements in overall survival compared with a
multikinase inhibitor.

The submitting company’s justification of the treatment’s cost in relation to its health
benefits was not sufficient and in addition the company did not present a sufficiently robust
economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE)
meeting.

The submitting company has indicated their intention to make a resubmission.